title: Tyrosine kinase inhibitors re-treatment beyond progression: choice and challenge.
abstract: Tyrosine kinase inhibitors (TKIs) are highly effective agents for the treatment of lung cancer which harbors activated gene mutation. However, for patients with failure of TKI, TKI re-treatment beyond progression (TRBP) is still a potential option that has been proven by many literatures. In this review, we summarize the clinical evidence of TRBP and discuss the potential mechanisms to overcome TKI-acquired resistance.
authors: 1 Department of Gerontology, Chengdu Military General Hospital, Chengdu 610083, China ; 2 Department of Oncology, the People's Hospital of Bishan County, Bishan, Chongqing 402760, China.
authors: Ru
authors: R
authors: Zhang
authors: 1 Department of Gerontology, Chengdu Military General Hospital, Chengdu 610083, China ; 2 Department of Oncology, the People's Hospital of Bishan County, Bishan, Chongqing 402760, China.
authors: Lingli
authors: L
authors: Tu
authors: 1 Department of Gerontology, Chengdu Military General Hospital, Chengdu 610083, China ; 2 Department of Oncology, the People's Hospital of Bishan County, Bishan, Chongqing 402760, China.
authors: Lan
authors: L
authors: Sun
keywords: EGFR; Non-small cell lung cancer (NSCLC); acquired resistance; re-treatment; tyrosine kinase inhibitor (TKI)